By Marleen Kaesebier and Bhanvi Satija March 27 (Reuters) - Swiss drugmaker Novartis will buy California-based biotech ...

The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than ...

At BIO Europe Spring, Pharmaceutical Technology interviewed executives and investors about regional competitiveness and ...

Vertex Pharmaceuticals makes most of its money from the sale of medicines for cystic fibrosis (CF), a rare disease that ...

On the lookout for its next blockbusters, Merck said it would buy Terns Pharmaceuticals, picking up a promising leukemia ...

With a 10.66% CAGR, Medical Biotechnology Emerges as the Cornerstone of Precision Medicine and Biopharmaceutical Innovation.Austin, United States, March 26, 2026 (GLOBE NEWSWIRE) -- Red Biotechnology ...

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $2.94, moving -6.67% from the previous trading session. This change lagged the S&P 500's daily loss of 1.67%. At the same time, ...

This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.

Collaboration leverages Converge Bio's proprietary generative AI to design and optimize novel tri-specific antibodies for oncology needsAI-driven ...

US pharma giant Merck & Co and Terns Pharmaceuticals, a clinical-stage oncology company, today announced that the companies ...

Merck has struck a $5.7bn deal to buy Terns Pharmaceuticals, a US biotech developing treatments for a rare form of blood and ...